» Articles » PMID: 14583065

Stimulating Adverse Drug Reaction Reporting: Effect of a Drug Safety Bulletin and of Including Yellow Cards in Prescription Pads

Overview
Journal Drug Saf
Specialties Pharmacology
Toxicology
Date 2003 Oct 30
PMID 14583065
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The effectiveness of voluntary reporting systems in pharmacovigilance highly depends on the number of assembled reports.

Aim: The aim of this study was to measure the effect of the periodical distribution of a bulletin on drug safety issues and of including yellow cards in prescription pads on the rate of adverse drug reaction (ADR) reporting.

Study Design And Methods: The Catalan Centre of Pharmacovigilance began its activities at the end of 1982. Since 1985, an ADR bulletin (ADRB) has been mailed approximately quarterly to all physicians in its catchment area, with one yellow card enclosed. Additionally, from 1991-1994, a yellow card was included in the prescription pads of the Catalan Health Service. Time series methodology, with adjustment of the monthly number of reports to an Auto-Regressive Integrated Moving Average (ARIMA) model, was used to evaluate the effect of these two measures.

Results: From January 1983-October 1995, 6240 spontaneous ADR reports were received, and 41 issues of the ADRB were sent out. Initially, the mean monthly spontaneous ADR reporting rate was 34.4 (SD = 14.1; n = 106 months). After the inclusion of yellow cards in prescription pads, the mean monthly spontaneous ADR reporting rate increased to 53.9 (SD = 14.4; n = 48 months). According to an ARIMA model, when a bulletin was send out (MONTH1), a mean increase of 9.4 reports was produced in that month, plus 12.3 additional reports in the following month (MONTH2), and 6.3 in the second month after sending the ADRB (MONTH3). A yellow card in the prescription pads elicits a monthly mean increase of 19.8 in the number of reports.

Conclusions: The present study suggests that ADRBs elicit a temporal increase of the ADR reporting rate. Including a yellow card in prescription pads was followed by an even greater increase in the reporting rate, possibly because it guarantees that yellow cards are available at the workplace.

Citing Articles

Improving adverse drug event reporting by healthcare professionals.

Shalviri G, Mohebbi N, Mirbaha F, Majdzadeh R, Yazdizadeh B, Gholami K Cochrane Database Syst Rev. 2024; 10:CD012594.

PMID: 39470185 PMC: 11520514. DOI: 10.1002/14651858.CD012594.pub2.


Time series analysis of using the PDCA method combined with the Teach-back method to improve spontaneous reports of adverse drug reactions in a grade IIIA hospital in China.

Li B, Jiang L, Liao L, Chen Y, Xu Z, Wu N Eur J Clin Pharmacol. 2023; 80(3):383-393.

PMID: 38151504 DOI: 10.1007/s00228-023-03601-5.


A Systematic Review of Pharmacovigilance Systems in Developing Countries Using the WHO Pharmacovigilance Indicators.

Garashi H, Steinke D, Schafheutle E Ther Innov Regul Sci. 2022; 56(5):717-743.

PMID: 35657484 PMC: 9356965. DOI: 10.1007/s43441-022-00415-y.


Time Series Disturbance Detection for Hypothesis-Free Signal Detection in Longitudinal Observational Databases.

Whalen E, Hauben M, Bate A Drug Saf. 2018; 41(6):565-577.

PMID: 29468602 DOI: 10.1007/s40264-018-0640-8.


Factors associated with the reporting of adverse drug reactions by health workers in nnewi Nigeria.

Ezeuko A, Ebenebe U, Nnebue C, Ugoji J Int J Prev Med. 2015; 6:25.

PMID: 25949775 PMC: 4387690. DOI: 10.4103/2008-7802.153862.


References
1.
Feely J, Moriarty S, OConnor P . Stimulating reporting of adverse drug reactions by using a fee. BMJ. 1990; 300(6716):22-3. PMC: 1661889. DOI: 10.1136/bmj.300.6716.22. View

2.
Crabtree B, Ray S, Schmidt P, OConnor P, Schmidt D . The individual over time: time series applications in health care research. J Clin Epidemiol. 1990; 43(3):241-60. DOI: 10.1016/0895-4356(90)90005-a. View

3.
Helfenstein U . Box-Jenkins modelling in medical research. Stat Methods Med Res. 1996; 5(1):3-22. DOI: 10.1177/096228029600500102. View

4.
Belton K . Attitude survey of adverse drug-reaction reporting by health care professionals across the European Union. The European Pharmacovigilance Research Group. Eur J Clin Pharmacol. 1997; 52(6):423-7. DOI: 10.1007/s002280050314. View